Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michele Reni

Showing results (1-10 of 231) with videos related to

Pageof 24
Sort By:
Current Drug Targets|March 31, 2012
Evidences and opinions for adjuvant therapy in pancreatic cancerMichele Reni
World Journal of Gastroenterology|October 19, 2010
Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing?Michele Reni
The Lancet. Oncology|January 2, 2021
APX005M, a CD40 monoclonal antibody, for patients with pancreatic adenocarcinomaMichele Reni
The Lancet. Oncology|July 10, 2022
Pancreatic cancer: still a cold case?Michele Reni, Giulia Orsi
JOP : Journal of the Pancreas|January 18, 2007
New therapies for pancreatic cancer: current standardMichele Reni, Stefano Cereda
The Lancet. Gastroenterology & Hepatology|December 15, 2022
Lessons and open questions in borderline resectable pancreatic cancerMichele Reni, Giulia Orsi
Expert Review of Anticancer Therapy|October 18, 2002
Current management and prognostic factors for adult ependymomaMichele Reni, Alba A Brandes
Critical Reviews in Oncology/Hematology|June 26, 2007
Primary central nervous system lymphomaAndrés J M Ferreri, Michele Reni
JAMA Oncology|January 26, 2023
Overall Survival With Adjuvant mFOLFIRINOX for Pancreatic CancerMichele Reni, Marina Macchini, Luca Porcu
Hematology/Oncology Clinics of North America|August 9, 2005
Prognostic factors in primary central nervous system lymphomasAndrés J M Ferreri, Michele Reni
Pageof 24

Showing results (1-10 of 231) with videos related to

Sort By:
Pageof 24
Current Drug Targets|March 31, 2012
Evidences and opinions for adjuvant therapy in pancreatic cancerMichele Reni
World Journal of Gastroenterology|October 19, 2010
Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing?Michele Reni
The Lancet. Oncology|January 2, 2021
APX005M, a CD40 monoclonal antibody, for patients with pancreatic adenocarcinomaMichele Reni
The Lancet. Oncology|July 10, 2022
Pancreatic cancer: still a cold case?Michele Reni, Giulia Orsi
JOP : Journal of the Pancreas|January 18, 2007
New therapies for pancreatic cancer: current standardMichele Reni, Stefano Cereda
The Lancet. Gastroenterology & Hepatology|December 15, 2022
Lessons and open questions in borderline resectable pancreatic cancerMichele Reni, Giulia Orsi
Expert Review of Anticancer Therapy|October 18, 2002
Current management and prognostic factors for adult ependymomaMichele Reni, Alba A Brandes
Critical Reviews in Oncology/Hematology|June 26, 2007
Primary central nervous system lymphomaAndrés J M Ferreri, Michele Reni
JAMA Oncology|January 26, 2023
Overall Survival With Adjuvant mFOLFIRINOX for Pancreatic CancerMichele Reni, Marina Macchini, Luca Porcu
Hematology/Oncology Clinics of North America|August 9, 2005
Prognostic factors in primary central nervous system lymphomasAndrés J M Ferreri, Michele Reni
Pageof 24